- Home
- RXRX vs HRMY Comparison
RXRX vs HRMY Comparison
Compare RXRX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- HRMY
- Stock Information
- Founded
- RXRX 2013
- HRMY 2017
- Country
- RXRX United States
- HRMY United States
- Employees
- RXRX N/A
- HRMY N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- HRMY Health Care
- Exchange
- RXRX Nasdaq
- HRMY Nasdaq
- Market Cap
- RXRX 2.4B
- HRMY 2.1B
- IPO Year
- RXRX 2021
- HRMY 2020
- Fundamental
- Price
- RXRX $4.71
- HRMY $32.06
- Analyst Decision
- RXRX Buy
- HRMY Strong Buy
- Analyst Count
- RXRX 4
- HRMY 9
- Target Price
- RXRX $7.25
- HRMY $55.33
- AVG Volume (30 Days)
- RXRX 17.0M
- HRMY 696.1K
- Earning Date
- RXRX 11-05-2025
- HRMY 10-28-2025
- Dividend Yield
- RXRX N/A
- HRMY N/A
- EPS Growth
- RXRX N/A
- HRMY 58.41
- EPS
- RXRX N/A
- HRMY 3.10
- Revenue
- RXRX $64,596,000.00
- HRMY $772,527,000.00
- Revenue This Year
- RXRX $24.09
- HRMY $20.09
- Revenue Next Year
- RXRX $20.99
- HRMY $16.86
- P/E Ratio
- RXRX N/A
- HRMY $10.40
- Revenue Growth
- RXRX 30.14
- HRMY 17.74
- 52 Week Low
- RXRX $3.79
- HRMY $26.47
- 52 Week High
- RXRX $12.36
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- RXRX 42.97
- HRMY 29.47
- Support Level
- RXRX $4.51
- HRMY $31.61
- Resistance Level
- RXRX $5.09
- HRMY $37.05
- Average True Range (ATR)
- RXRX 0.26
- HRMY 1.16
- MACD
- RXRX 0.04
- HRMY -0.56
- Stochastic Oscillator
- RXRX 40.63
- HRMY 6.82
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.